Hear colorectal cancer patient Angela Gengler share her experience with COVID-19 and how it impacted her surveillance plan. Her doctor was able to order mobile Signatera so that she could have her biopsy drawn from home.
Brooks, a young-onset patient, talks about her experience with Signatera.
Casey talks about her experience using Signatera to detect molecular residual disease (MRD)
Listen as Alexey Aleshin, MD, Gregory Botta, MD, PhD, Sarah Louden, and Manju George, DVM, PhD, dive into tools for surveillance that directly impact colorectal cancer care, including ctDNA and MRD testing.
Presented by Dr. Alexey Aleshin, Natera’s senior medical director of oncology.
For each featured testing option, we have worked with the test provider to describe , We continue to add new sections over time, so be sure to check back often!